1. Search Result
Search Result
Results for "

nicotinamide mononucleotide

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-F0004
    Fosribnicotinamide
    25+ Cited Publications

    β-nicotinamide mononucleotide; β-NM; NMN

    Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide
  • HY-129522
    Sulfo-ara-F-NMN
    5+ Cited Publications

    CZ-48

    Toll-like Receptor (TLR) Neurological Disease
    Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC50 around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production .
    Sulfo-ara-F-NMN
  • HY-126255
    SBI-797812
    2 Publications Verification

    NAMPT Metabolic Disease
    SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD +. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD + in mice .
    SBI-797812
  • HY-W615108B

    NMNH disodium

    Endogenous Metabolite Cancer
    β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD + and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
    β-Nicotinamide mononucleotide, reduced form disodium
  • HY-F0004S

    β-nicotinamide mononucleotide-d4; β-NM-d4; NMN-d4

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide-d4
  • HY-W015764
    T-1105
    2 Publications Verification

    Flavivirus Infection
    T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase .
    T-1105
  • HY-F0004R

    β-nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)

    Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004 ). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide (Standard)
  • HY-P2940

    NAMPT Inflammation/Immunology
    NADase is an ectoenzyme/membrane-bound enzyme targeting nicotinamide adenine dinucleotide (NAD +). NADase regulates intracellular NAD + homeostasis by hydrolyzing NAD + into nicotinamide mononucleotide (NMN) and ADP-ribose. NADase is promising for research of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders .
    NADase
  • HY-177843

    Liposome Metabolic Disease
    Liposomal NMN is a specialized delivery system that encapsulates NMN within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NMN. NMN (β-Nicotinamide Mononucleotide) is a naturally occurring key met
    Liposomal NMN
  • HY-W615108BR

    Endogenous Metabolite Reference Standards Cancer
    β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
    β-Nicotinamide mononucleotide, reduced form disodium (Standard)
  • HY-119159

    NAMPT Caspase Apoptosis Cancer
    AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC50 of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia .
    AS1604498

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: